Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME

22 January, 2020

Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial

07 October, 2019

Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board

17 September, 2019

Why a pharma investor quit his day job to follow a vision (Guest interview)

16 May, 2019

Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment

04 January, 2019

Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round

04 January, 2019

Oculis Strengthens its Global Clinical and Business Development Capabilities

20 November, 2018

Oculis appoints Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

25 September, 2018

Oculis elects Anthony Rosenberg David A. Weber to its Board of Directors

19 September, 2018